U.S. Food and Drug Administration

Drug advertising rules generally require prescription drug companies to disclose risks and side effects in traditional mass-media advertising (such as magazines and television) and prohibit promotion of a drug for conditions that are not approved by the U.S. Food and Drug Administration, with violations subject to FDA enforcement.

The U.S. Food and Drug Administration advises that clinicians should consider minimizing the use of acetaminophen during pregnancy because evidence is inconclusive about whether prenatal acetaminophen exposure is linked to autism.

The U.S. Food and Drug Administration's limit for lead from any single dietary supplement product is 5 micrograms per day.

The U.S. Food and Drug Administration's Interim Reference Level (IRL) for total daily lead exposure is 8.8 micrograms per day for people who could become pregnant, 2.2 micrograms per day for children, and 12.5 micrograms per day for all other adults.

The U.S. Food and Drug Administration does not review, approve, or test dietary supplements such as protein powders before they are sold.

A 2025 Consumer Reports analysis of 23 powder and ready-to-drink protein products used the California Office of Environmental Health Hazard Assessment's 0.5 micrograms-per-day threshold and found that 16 of 23 products exceeded 0.5 micrograms of lead per serving, four of 23 exceeded 2.2 micrograms of lead per serving, and two products contained 72% and 88% respectively of the FDA's total daily lead amount for pregnant people.

In 2023, the U.S. Food and Drug Administration approved Syfovre as the first drug specifically indicated to treat geographic atrophy; Syfovre is administered by intravitreal injection and can slow disease progression but does not reverse established vision loss.

The U.S. Food and Drug Administration approved the use of bacteriophages on ready-to-eat meats in 2006, with typical application methods including surface sprays.

The U.S. Food and Drug Administration states that gray-market GLP-1 drugs obtained outside the legal drug supply chain are not evaluated for safety, quality, or efficacy and may be counterfeit, contaminated, or improperly compounded.

Long-term exposure to even low doses of Cesium-137 is associated with an elevated risk of cancer, according to health authorities such as the U.S. Food and Drug Administration.

U.S. Food and Drug Administration (FDA) approval allows mifepristone to be prescribed within 10 weeks of conception.

Detection of Clostridium botulinum in infant formula is difficult, and a negative laboratory test result does not definitively rule out the presence of the bacterium in the product.

The U.S. Food and Drug Administration (FDA) licenses vaccines, and the Centers for Disease Control and Prevention (CDC) promotes FDA-licensed vaccines.